OBJECTIVE: This study assessed the single-dose pharmacokinetics of the herpes antiviral acyclovir (administered as the pro-drug valacyclovir) alone and in combination with twice-daily 200 mg ritonavir-boosted tipranavir (500 mg) at steady state. METHODS: The study was an open label, one-sequence cross-over pharmacokinetic study in HIV-negative adults. Plasma drug concentrations were measured by validated LC/MS/MS assays; pharmacokinetics (AUC, C(max)) were determined using noncompartmental methods. The geometric mean ratio and 90% confidence interval [GMR, 90% CI] were used to evaluate the drug interaction. RESULTS:Twenty-six of 29 subjects completed the trial. With steady-state tipranavir/ritonavir, acyclovir C(max) decreased 4.9% [0.95, 0.88-1.02] and AUC increased 6.6% [1.07, 1.04-1.09]. The majority of subjects experienced at least one adverse event, most of which were mild gastrointestinal disorders. Three subjects discontinued tipranavir/ritonavir treatment as a result of drug-related increases in ALT/AST, including one subject who experienced mild upper abdominal pain. All subjects recovered without sequelae. CONCLUSIONS: When administered as a single dose of valacyclovir with steady-state tipranavir/ritonavir, there were no clinically important changes in acyclovir pharmacokinetics. This result indicates that valacyclovir can be co-administered safely with no dose adjustments.
RCT Entities:
OBJECTIVE: This study assessed the single-dose pharmacokinetics of the herpes antiviral acyclovir (administered as the pro-drug valacyclovir) alone and in combination with twice-daily 200 mg ritonavir-boosted tipranavir (500 mg) at steady state. METHODS: The study was an open label, one-sequence cross-over pharmacokinetic study in HIV-negative adults. Plasma drug concentrations were measured by validated LC/MS/MS assays; pharmacokinetics (AUC, C(max)) were determined using noncompartmental methods. The geometric mean ratio and 90% confidence interval [GMR, 90% CI] were used to evaluate the drug interaction. RESULTS: Twenty-six of 29 subjects completed the trial. With steady-state tipranavir/ritonavir, acyclovir C(max) decreased 4.9% [0.95, 0.88-1.02] and AUC increased 6.6% [1.07, 1.04-1.09]. The majority of subjects experienced at least one adverse event, most of which were mild gastrointestinal disorders. Three subjects discontinued tipranavir/ritonavir treatment as a result of drug-related increases in ALT/AST, including one subject who experienced mild upper abdominal pain. All subjects recovered without sequelae. CONCLUSIONS: When administered as a single dose of valacyclovir with steady-state tipranavir/ritonavir, there were no clinically important changes in acyclovir pharmacokinetics. This result indicates that valacyclovir can be co-administered safely with no dose adjustments.
Authors: J Martin; G Deslandes; E Dailly; C Renaud; V Reliquet; F Raffi; P Jolliet Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2009-08-03 Impact factor: 3.205
Authors: Geoffrey Mukwaya; Thomas MacGregor; David Hoelscher; Thomas Heming; Daniel Legg; Kelli Kavanaugh; Phillip Johnson; John P Sabo; Scott McCallister Journal: Antimicrob Agents Chemother Date: 2005-12 Impact factor: 5.191
Authors: J B Dumond; M Vourvahis; N L Rezk; K B Patterson; H-C Tien; N White; S H Jennings; S O Choi; J Li; M J Wagner; N M La-Beck; M Drulak; J P Sabo; M A Castles; T R Macgregor; A D M Kashuba Journal: Clin Pharmacol Ther Date: 2010-02-10 Impact factor: 6.875
Authors: Linzhi Chen; John P Sabo; Elsy Philip; Yanping Mao; Stephen H Norris; Thomas R MacGregor; Jan M Wruck; Sandra Garfinkel; Mark Castles; Amy Brinkman; Hernan Valdez Journal: Antimicrob Agents Chemother Date: 2007-05-07 Impact factor: 5.191
Authors: R Douglas Bruce; Frederick L Altice; David E Moody; Shen-Nan Lin; Wenfang B Fang; John P Sabo; Jan M Wruck; Peter J Piliero; Carolyn Conner; Laurie Andrews; Gerald H Friedland Journal: Drug Alcohol Depend Date: 2009-09-01 Impact factor: 4.492